The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine

Biomaterials

Volumn 31, Issue 6, 2010, Pages 1420-1428

  Alshamsan, Aws ^a   Hamdy, Samar ^a   Samuel, John ^a   El Kadi, Ayman O S ^a   Lavasanifar, Afsaneh ^a   Uludaǧ, Hasan ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer therapy; Melanoma; Nanomedicine; Polyethylenimine; siRNA; STAT3

Indexed keywords

CELL DEATH; DERMATOLOGY; DISEASES; MEDICAL NANOTECHNOLOGY; ONCOLOGY; RNA; TUMORS;

CANCER THERAPY; MELANOMA; POLYETHYLENIMINES; SIRNA; STAT3;

GENE THERAPY;

CASPASE 3; INTERLEUKIN 6; NANOPARTICLE; POLYETHYLENEIMINE; POLYMER; SMALL INTERFERING RNA; STAT3 PROTEIN; STEARIC ACID; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL VIABILITY; CHEMICAL MODIFICATION; CLINICAL EFFECTIVENESS; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVITY; GENE SILENCING; IN VIVO STUDY; MALE; MELANOMA; MELANOMA B16; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; TISSUE LEVEL; TUMOR REGRESSION; TUMOR VOLUME;

EID: 72149101228     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.11.003     Document Type: Article

References (58)

1. Jing N., and Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 16 6 (2005) 601-607
2. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
3. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8 (2002) 945-954
4. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 5220 (1995) 81-83
5. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 2 (2004) 97-105
6. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63 6 (2003) 1270-1279
7. Bharti A.C., Donato N., and Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171 7 (2003) 3863-3871
8. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276 48 (2001) 45443-45455
9. Liu X., Li J., and Zhang J. STAT3-decoy ODN inhibits cytokine autocrine of murine tumor cells. Cell Mol Immunol 4 4 (2007) 309-313
10. Deng J., Grande F., and Neamati N. Small molecule inhibitors of Stat3 signaling pathway. Curr Cancer Drug Targets 7 1 (2007) 91-107
11. Yue P., and Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 18 1 (2009) 45-56
12. Cejka D., Losert D., and Wacheck V. Short interfering RNA (siRNA): tool or therapeutic?. Clin Sci (Lond) 110 1 (2006) 47-58
13. Gao L.F., Xu D.Q., Wen L.J., Zhang X.Y., Shao Y.T., and Zhao X.J. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 26 3 (2005) 377-383
14. Konnikova L., Kotecki M., Kruger M.M., and Cochran B.H. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 (2003) 23
15. Omidi Y., Hollins A.J., Benboubetra M., Drayton R., Benter I.F., and Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 11 6 (2003) 311-323
16. Thomas M., Lu J.J., Chen J., and Klibanov A.M. Non-viral siRNA delivery to the lung. Adv Drug Deliv Rev 59 2-3 (2007) 124-133
17. Uprichard S.L. The therapeutic potential of RNA interference. FEBS Lett 579 26 (2005) 5996-6007
18. Kennedy D. Breakthrough of the year. Science 298 5602 (2002) 2283
19. Behlke M.A. Progress towards in vivo use of siRNAs. Mol Ther 13 4 (2006) 644-670
20. Putnam D., and Doody A. RNA-interference effectors and their delivery. Crit Rev Ther Drug Carrier Syst 23 2 (2006) 137-164
21. Demeneix B., and Behr J.P. Polyethylenimine (PEI). Adv Genet 53 (2005) 217-230
22. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol 124 1 (2006) 12-25
23. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., and Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12 5 (2005) 461-466
24. Lungwitz U., Breunig M., Blunk T., and Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60 2 (2005) 247-266
25. Godbey W.T., Wu K.K., and Mikos A.G. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J Biomed Mater Res 45 3 (1999) 268-275
26. Alshamsan A., Haddadi A., Incani V., Samuel J., Lavasanifar A., and Uludag H. Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm 6 1 (2009) 121-133
27. Kataoka K., Kim D.J., Carbajal S., Clifford J.L., and DiGiovanni J. Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. Carcinogenesis 29 6 (2008) 1108-1114
28. Incani V., Tunis E., Clements B.A., Olson C., Kucharski C., Lavasanifar A., et al. Palmitic acid substitution on cationic polymers for effective delivery of plasmid DNA to bone marrow stromal cells. J Biomed Mater Res A 81 2 (2007) 493-504
29. Grandis J.R., Drenning S.D., Chakraborty A., Zhou M.Y., Zeng Q., Pitt A.S., et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest 102 7 (1998) 1385-1392
30. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62 22 (2002) 6659-6666
31. Wang W., Edington H.D., Rao U.N., Jukic D.M., Wang H., Shipe-Spotloe J.M., et al. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol 128 8 (2008) 1997-2002
32. Darnell J.E. Validating Stat3 in cancer therapy. Nat Med 11 6 (2005) 595-596
33. Al Zaid Siddiquee K., and Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18 2 (2008) 254-267
34. Xiong H., Zhang Z.G., Tian X.Q., Sun D.F., Liang Q.C., Zhang Y.J., et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10 3 (2008) 287-297
35. Sparano J.A., Moulder S., Kazi A., Coppola D., Negassa A., Vahdat L., et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 15 8 (2009) 2942-2948
36. Graness A., Poli V., and Goppelt-Struebe M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochem Pharmacol 72 1 (2006) 32-41
37. Mackenzie G.G., Queisser N., Wolfson M.L., Fraga C.G., Adamo A.M., and Oteiza P.I. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 123 1 (2008) 56-65
38. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14 14 (2008) 4491-4499
39. Gilmore I.R., Fox S.P., Hollins A.J., and Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 3 2 (2006) 145-155
40. Zhou W., Grandis J.R., and Wells A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br J Cancer 95 2 (2006) 164-171
41. Niu G., Shain K.H., Huang M., Ravi R., Bedi A., Dalton W.S., et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 61 8 (2001) 3276-3280
42. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116 2 (2006) 123-129
43. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 129 2 (2008) 107-116
44. Hsiao Y.W., Liao K.W., Chung T.F., Liu C.H., Hsu C.D., and Chu R.M. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 57 7 (2008) 1091-1104
45. Rakemann T., Niehof M., Kubicka S., Fischer M., Manns M.P., Rose-John S., et al. The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro. J Biol Chem 274 3 (1999) 1257-1266
46. Haan S., Keller J.F., Behrmann I., Heinrich P.C., and Haan C. Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell Signal 17 12 (2005) 1542-1550
47. Costa-Pereira A.P., Tininini S., Strobl B., Alonzi T., Schlaak J.F., Is'harc H., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A 99 12 (2002) 8043-8047
48. Kakuta S., Tagawa Y., Shibata S., Nanno M., and Iwakura Y. Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 105 1 (2002) 92-100
49. Costanzo C., Piacentini G., Vicentini L., Armenante F., Mazzi P., Savio C., et al. Cell-specific differences in the regulation of IL-6 expression by PMA. Biochem Biophys Res Commun 260 3 (1999) 577-581
50. Libermann T.A., and Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10 5 (1990) 2327-2334
51. Kortylewski M., Kujawski M., Herrmann A., Yang C., Wang L., Liu Y., et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res 69 6 (2009) 2497-2505
52. Nishinakamura H., Minoda Y., Saeki K., Koga K., Takaesu G., Onodera M., et al. An RNA-binding protein alphaCP-1 is involved in the STAT3-mediated suppression of NF-kappaB transcriptional activity. Int Immunol 19 5 (2007) 609-619
53. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 1 (2004) 48-54
54. Yu Z., Zhang W., and Kone B.C. Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB. Biochem J 367 Pt 1 (2002) 97-105
55. Yang J., and Stark G.R. Roles of unphosphorylated STATs in signaling. Cell Res 18 4 (2008) 443-451
56. Chen Z., and Han Z.C. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28 2 (2008) 185-200
57. Ghosh S., and Maity P. Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Int Immunopharmacol 7 13 (2007) 1598-1608
58. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59 20 (1999) 5059-5063